We live in an era marked by rapid advancements in our understanding of ocular surface diseases and dry eyes, offering a renewed hope for millions affected worldwide. Dry eye disease (DED) remains a prevalent ocular condition, causing discomfort, visual disturbances, and potential harm to the eye’s surface. Yet, amidst these challenges, breakthrough technologies like TearStim are revolutionising treatment approaches.

TearStim works by stimulating the meibomian glands to support natural tear production. It may ease dry eye symptoms for some people, and results vary. Dr Moorthy will explain whether it may suit you.

When integrated seamlessly into modern DED management plans, TearStim complements existing strategies. Starting with a thorough assessment of patient symptoms and ocular health, personalised treatment regimens may include TearStim alongside other therapies like lubricating eye drops and environmental adjustments.

Ongoing research and clinical trials continue to refine these management plans. TearStim is one treatment that targets the meibomian glands, and results vary from person to person. Email us for more information at concierge@eyehub.net.au.